Solara Active Pharma Sciences' Q1 FY 2025-26 Quarterly Results

Result Summary

• Solara Active Pharma Sciences Ltd reported a 6.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 12.1%.
• Its expenses for the quarter were down by 10.4% QoQ and 18.0% YoY.
• The net profit decreased 104.1% QoQ and decreased 178.2% YoY.
• The earnings per share (EPS) of Solara Active Pharma Sciences Ltd stood at 2.5 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Solara Active Pharma Sciences Ltd is a pharmaceutical company operating primarily in the active pharmaceutical ingredients (API) segment. The company is known for manufacturing and supplying APIs and has a robust presence in the pharmaceutical industry. Solara Active Pharma Sciences Ltd focuses on catering to the needs of the global pharmaceutical sector with a diverse portfolio of products. As of the latest updates available up to October 2023, the company is recognized for its strategic initiatives in expanding its market reach and enhancing its manufacturing capabilities. However, specific recent developments or changes in the company's strategic direction within the past quarter are not detailed in the provided data.

Revenue

During the first quarter of the fiscal year 2026 (Q1FY26), Solara Active Pharma Sciences Ltd reported a total income of ₹320.13 crores. This represents a 6.3% increase from the previous quarter (Q4FY25), where the total income was ₹301.13 crores. However, compared to the same quarter in the previous fiscal year (Q1FY25), there is a noticeable decline of 12.1% from ₹364.05 crores. The quarter-over-quarter (QoQ) growth suggests a recovery in revenue from the previous quarter, while the year-over-year (YoY) decline indicates a significant decrease in revenue compared to the same period last year.

Profitability

The profitability of Solara Active Pharma Sciences Ltd has shown a turnaround in Q1FY26 with a Profit After Tax (PAT) of ₹10.52 crores, compared to a loss of ₹255.23 crores in Q4FY25. This shift marks a substantial improvement on a QoQ basis. Year-over-year, the company has also moved from a loss of ₹13.46 crores in Q1FY25 to a profit, indicating a notable improvement in financial performance. The Earnings Per Share (EPS) has increased to ₹2.50 in Q1FY26 from a negative EPS of ₹70.90 in the previous quarter, and from ₹-3.50 in Q1FY25. This reflects a significant enhancement in shareholder value compared to both the prior quarter and year.

Operating Metrics

Total expenses for Q1FY26 amounted to ₹309.61 crores, marking a decrease of 10.4% from Q4FY25, where expenses stood at ₹345.61 crores. Compared to Q1FY25, expenses have reduced by 18.0% from ₹377.51 crores. The reduction in expenses on both QoQ and YoY bases suggests a decrease in operational costs or a more efficient cost management strategy in the current quarter. There was no tax liability reported in Q1FY26, in contrast to the previous quarter's tax outlay of ₹88.79 crores, further impacting the company's profitability positively. The data does not provide enough granularity to calculate certain financial ratios such as P/E ratio, debt-to-equity ratio, or current ratio, as specific data points like market capitalization, debt levels, or current assets/liabilities are not included.